Market Overview - The Hang Seng Index closed down by 0.38% and the Hang Seng Tech Index fell by 0.69% [1] - The Hong Kong Tech ETF (159751) decreased by 0.64%, while the Hang Seng Hong Kong Stock Connect ETF (159318) dropped by 0.14% [1] Sector Performance - Industrial group enterprises and home goods sectors showed the highest gains [1] - Water utilities and life sciences tools sectors experienced the largest declines [1] Individual Stock Movements - Shandong Gold increased by 7.01%, Zhaojin Mining rose by 6.37%, and Zijin Mining International gained 6.19% [1] - Xiansheng Pharmaceutical fell by 5.76%, and Zhongqing Shares dropped by 7.18% [1] - Reshaping Energy surged by 29.38%, and Universal Gold Group rose by 10.6% [1]

Core Viewpoint - The Hong Kong stock market experienced a decline, with the Hang Seng Index falling by 0.28% and the Hang Seng Tech Index dropping by 0.8% [1] Market Performance - The Hong Kong Technology ETF (159751) decreased by 1.76% [1] - The Hang Seng Hong Kong Stock Connect ETF (159318) fell by 0.64% [1] Sector Performance - The oil and gas sector and passenger airline companies showed positive performance, leading the gains [1] - The communication equipment and life sciences tools sectors faced significant declines [1] Individual Stock Performance - Yaoshi Bang (药师帮) saw a drop of 8.12% [1] - Haotian International Construction Investment (昊天国际建投) fell by 10.05% [1] - Longpan Technology (龙蟠科技) increased by 9.29% [1] - Yihua Tong (亿华通) rose by 7.73% [1]

Core Viewpoint - The Hong Kong stock market experienced a decline, with the Hang Seng Index falling by 0.94% and the Hang Seng Tech Index dropping by 1.41% [1] Market Performance - The Hong Kong Technology ETF (159751) decreased by 1.95% - The Hang Seng Hong Kong Stock Connect ETF (159318) fell by 1.34% [1] Sector Performance - Industrial group enterprises, hotels, and resort REITs showed strong gains - The automotive and life sciences tools sectors faced significant declines [1] Individual Stock Movements - Base Champion Group surged over 83% - Lao Pu Gold dropped by 8.21% - Mongol Mining fell by 9.45% - China Aluminum International (601068) increased by 30.52% - Yaojie Ankang-B rose by 11.18% [1]

Market Overview - The Hang Seng Index closed down by 0.76%, while the Hang Seng Tech Index decreased by 0.58% [1] - The Hong Kong Tech ETF (159751) rose by 0.91%, and the Hang Seng Hong Kong Stock Connect ETF (159318) fell by 0.21% [1] Sector Performance - The communication equipment, electronic devices, and instruments sectors showed strong gains [1] - The life sciences tools and passenger airlines sectors experienced significant declines [1] Individual Stock Movements - Lens Technology increased by 12.63%, Shandong Gold rose by 7.23%, Zhaojin Mining gained 6.35%, WuXi Biologics went up by 6.09%, and SMIC climbed by 5.16% [1] - China National Railway fell by 13.33%, and Longi Green Energy dropped by 7.81% [1] - Shandong High-speed Holdings surged by 29.76%, and MIRXES-B increased by 27.68% [1]

Bio-Techne FY Conference Summary Company Overview - **Company**: Bio-Techne (NasdaqGS: TECH) - **Industry**: Life Science Tools Key Points Company Positioning and Growth Strategy - Bio-Techne is a leader in reagents for life science research, focusing on proteins, antibodies, and assays for diagnostics and therapeutics [4][6] - The company has invested heavily in automation of protein analytics, spatial biology, and cell therapy, which now account for approximately 45% of revenue, up from 30% pre-COVID [6][7] - 90% of Bio-Techne's business is recurring, primarily from consumables, which supports sustainable growth [7] Recent Financial Performance - The company reported a 3% growth in the most recent quarter, with notable performance in China (10% growth) and continued double-digit growth in large pharma [9][10] - Challenges included delays in shipping high-priced instruments due to geopolitical issues [9] Academic Market Exposure - Academic sales account for about 20% of total revenue, with U.S. academia contributing approximately 11-12% [13][14] - Despite funding constraints, consumables have remained flat, indicating resilience in the product portfolio [14][15] Market Dynamics in China - Positive sentiment in China suggests a gradual ramp-up in growth, with expectations of returning to double-digit growth in the long term [18][19] Biopharma Market Insights - Biopharma constitutes roughly 50% of revenue, with large pharma showing strong recovery and growth, while biotech funding has decreased significantly [20][21] - The uncertainty in biotech funding may impact future spending, but recent improvements in funding could signal a recovery [22] Cell Therapy Business - Bio-Techne is well-positioned in the cell therapy market, focusing on GMP proteins, with a significant increase in revenue from this segment [23][24] - The company has built a strong reputation for quality and has a competitive edge in the regen med space, which has greater market potential than CAR-T therapies [25][26] Core Reagents and Instrumentation - The core reagents business remains stable, with healthy competition in the antibody market [30][31] - The ProteinSimple platform has shown resilience, with growth driven by increased usage of consumables despite a downturn in new instrument placements [34][36] Spatial Biology and Competitive Position - Bio-Techne leads in spatial biology with RNAscope reagents and the new COMET instrument, which automates RNA and protein detection [39][41] - The company is positioned to capitalize on the growing demand for translational research tools [40] Strategic Divestiture - The recent divestiture of the Exosome Diagnostics business was driven by a misalignment with Bio-Techne's core capabilities and a lack of a clear path to profitability [43][45] Revenue Outlook and Market Conditions - The company anticipates low single-digit growth, managing costs and investments amid market uncertainties [47][50] - Optimism remains regarding recovery in key markets, with expectations that administrative-induced noise will settle down [51][53] Conclusion Bio-Techne is strategically positioned for growth in the life science tools industry, with a strong focus on automation, spatial biology, and cell therapy. Despite current market challenges, the company maintains a positive outlook for future performance driven by its recurring revenue model and innovative product offerings.

Market Performance - The Hang Seng Index increased by 2.58% and the Hang Seng Tech Index rose by 3.52% [1] - The Hong Kong Tech ETF (159751) gained 3.11%, while the Hang Seng Hong Kong Stock Connect ETF (159318) increased by 2.2% [1] Sector Performance - The life sciences tools and pharmaceuticals sectors showed the highest gains [1] - The computer and peripheral devices, as well as forestry and paper products sectors, experienced the largest declines [1] Individual Stock Performance - Tencent Music (SW) surged by 15.63%, followed by Innovent Biologics with an increase of 8.82% [1] - Other notable gainers include CSPC Pharmaceutical (6.77%), WH Group (6.23%), WuXi AppTec (6.19%), Alibaba (6.09%), and Alibaba WR (5.51%) [1] - On the downside, Qutoutiao fell by 7.07% and 361 Degrees dropped by 9.29% [1] - Noteworthy increases also included China Literature with a rise of 19.61% and Hon Teng Precision Technology up by 11.78% [1]

Financial Data and Key Metrics Changes - Revenue for Q2 2025 was $47.4 million, down from $69.4 million in Q2 2024. Excluding high volume Clean Cap, base revenue increased by 5% year-over-year [19][20] - GAAP net loss before non-controlling interests was $69.8 million for Q2 2025, compared to a loss of $18.4 million in Q2 2024 [20] - Adjusted EBITDA was negative $10.4 million for Q2 2025, down from a positive $13 million in Q2 2024 [21] - Basic and diluted EPS for Q2 2025 was a loss of $0.27 per share, compared to a loss of $0.07 per share in Q2 2024 [21] Business Line Data and Key Metrics Changes - Nucleic Acid Production (NAP) segment revenue was $31.1 million in Q2 2025, with base NAP business excluding high volume Clean Cap up 3% year-over-year [23] - Biologics Safety Testing (BST) segment revenue was $16.3 million in Q2 2025, reflecting a 10% year-over-year increase [24] - Adjusted EBITDA for BST was $10.9 million, resulting in an adjusted EBITDA margin of 67% [24] Market Data and Key Metrics Changes - Revenue by customer type in Q2 2025: 28% biopharma, 30% life sciences and diagnostics, 8% academia, 7% CRO, CMO, CDMO, and 27% to distributors [19] - Revenue by geography: 65% North America, 18% EMEA, 12% Asia Pacific (excluding China), and 5% in China [19] Company Strategy and Development Direction - The company is committed to improving operational excellence and execution through a restructuring plan aimed at reducing annualized expenses by over $15 million [6][7] - Focus on revenue diversification and growth across business segments, particularly in BST and NAP, with investments in new analytical products [10][11] - The company aims to return to sustainable positive adjusted EBITDA and free cash flow by 2026 [14] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the need for a stronger culture of accountability and operational discipline to drive results [5] - The CEO expressed optimism about the company's future, emphasizing the potential for growth and profitability despite current challenges [15] - The leadership team is focused on stabilizing the organization and exploring further growth opportunities post-restructuring [111] Other Important Information - The company has initiated a comprehensive business review and has withdrawn prior guidance for 2025, planning to reinstate guidance after completing the review [27] - Anticipated restructuring charges of approximately $8 million to $9 million in 2025, primarily for employee severance and related expenses [26] Q&A Session Summary Question: Guidance philosophy and visibility for 2026 targets - Management is focused on controlling costs and gaining confidence in the numbers shared, with no specific red flags indicating incorrect guidance [36][40] Question: Durability of BST improvement and pull forward dynamics - BST showed strong growth, with no significant pull forward dynamics from China or Asia impacting Q2 results [41][43] Question: Growth potential in China - Management expects China to become a growth driver as relations between the U.S. and China improve [47] Question: Impact of tariffs on CDMO business - Currently, there has been little movement regarding tariffs, but potential opportunities exist if tariffs lead to U.S. production shifts [51] Question: Positive surprises and challenges in the business review - Management was surprised by the extent of expenditures and the loyalty of customers in the preclinical to phase three segments [56][58] Question: E-commerce revenue potential - E-commerce currently represents a small percentage of revenue, but management sees significant potential for growth in this area [75][78] Question: Long-term margin potential - Management aims to restore profitability and free cash flow before addressing long-term margin targets [92][94]

Financial Data and Key Metrics Changes - Total revenue for Q2 2025 was $24.5 million, down 29% year over year due to temporary funding pauses and uncertainty in the U.S. academic and pharmaceutical end markets [15][16] - Gross profit was $11.3 million with a gross margin of 46.2%, while non-GAAP gross profit was $10.2 million with a non-GAAP gross margin of 41.8% [17][18] - Operating expenses increased to $48.4 million, up $15.2 million year over year, including significant costs related to acquisition and restructuring [19] - Adjusted EBITDA was a loss of $13.7 million compared to a loss of $4.1 million in the same quarter of the previous year [19] Business Line Data and Key Metrics Changes - Consumable revenue was $14.9 million, while instrument revenue was $2 million, with 10 instruments placed in the quarter compared to 22 in the previous year [16] - Accelerator lab revenue was $4 million, down 60%, driven by a decline in large multimillion-dollar projects from pharmaceutical customers [16] - Sales to diagnostics partners totaled $2.6 million, up from $0.7 million in the prior year period [16] Market Data and Key Metrics Changes - The customer mix was evenly split between pharma and academia, with academic sales declining 18% and pharma sales declining 38% [16] - The combined company expects to report $130 million to $135 million of revenue for 2025, with Simoa revenue expected to be $100 million to $105 million [21][22] Company Strategy and Development Direction - The company completed the transformative Equaya acquisition and is focused on sustainable double-digit revenue growth and margin improvement [6][7] - The strategic priorities include expanding the addressable market, accelerating the Simoa platform rollout, and building a foundation for an Alzheimer's diagnostic franchise [10][11][13] - The company aims to achieve approximately $85 million in synergy savings and cost reductions by 2026, with 75% of these expense reductions already implemented [7][23] Management's Comments on Operating Environment and Future Outlook - Management acknowledged temporary headwinds in academic funding and biopharma spending but expressed confidence in the long-term growth potential of proteomics [6][9] - The company is committed to achieving cash flow breakeven in 2026, even amidst challenging market conditions, and has already exceeded synergy expectations [24][25] Other Important Information - The company ended the quarter with $263.8 million in cash and equivalents, with adjusted cash usage improving by 49% year over year [20] - Akoya generated $18.2 million in Q2, contributing to the combined company's revenue outlook [21] Q&A Session Summary Question: Insights on Accelerator business and clinical trials - The Accelerator business grew approximately 40% year on year, with a net increase in customers, although project sizes are smaller than last year [29][30] Question: Academic funding outlook and customer confidence - There is strong resiliency in the consumables franchise, with approximately $100 million in consumables revenue, indicating potential positivity in academic funding [31][32] Question: Cost actions and long-term growth - The integration has focused on operating as one company, realizing significant synergies in operations and maintaining a focus on customer service while addressing cost structures [35][36]

Financial Data and Key Metrics Changes - The company reported adjusted EPS of $0.53 for Q4, up from $0.49 in the prior year, while GAAP EPS was a loss of $0.11 compared to a profit of $0.25 in the previous year [28] - Q4 revenue reached $317 million, reflecting a 3% organic growth year-over-year and a 4% reported growth [28] - Total adjusted gross margin was 70.1% in Q4, down from 71.1% the previous year, primarily due to an unfavorable product mix [29] Business Line Data and Key Metrics Changes - The Protein Sciences segment reported sales of $226.5 million, with organic revenue growth of 4% for the quarter, driven by strong performances in cell therapy and protein analytical tools [32] - The Diagnostics and Spatial Biology segment saw Q4 sales of $89.7 million, with both reported and organic growth decreasing by 1% compared to the same period last year [32] - The divestiture of the Exosome Diagnostics business is expected to improve the operating margin in the Diagnostics and Spatial Biology segment [35] Market Data and Key Metrics Changes - Biopharma end market delivered high single-digit growth for both Q4 and the full fiscal year, driven by large pharmaceutical customers [13] - Academic revenue represented approximately 21% of total business, with U.S. institutions contributing roughly 12%, and the exposure to NIH funding was reassessed to be less than one-third [14][15] - China experienced low double-digit growth in Q4, attributed to demand improvement ahead of anticipated tariff impacts [17] Company Strategy and Development Direction - The company announced the divestiture of its exosome diagnostics business to focus on core growth pillars and improve profitability [10][11] - Strategic investments will be redirected towards advancing automated proteomic analysis and spatial biology platforms, as well as expanding applications in cell therapy [39] - The company aims to achieve adjusted operating margin expansion of approximately 100 basis points in fiscal year 2026 compared to fiscal year 2025 [40] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating a dynamic market environment, with expectations of low single-digit organic growth until uncertainties around NIH funding and pharmaceutical tariffs are resolved [38] - The company remains optimistic about long-term growth drivers, including an aging global population and increasing demand for life sciences innovations [39] - Management noted that the current cautious purchasing behavior among U.S. academic customers is expected to persist until funding uncertainties are clarified [92] Other Important Information - The company generated $98.2 million in cash from operations in Q4 and returned $12.4 million in dividends and $100.1 million through stock buybacks [31] - The balance sheet ended Q4 with $162.2 million in cash and total leverage well below one times EBITDA [31] Q&A Session Summary Question: Clarification on growth outlook for fiscal year 2026 - Management clarified that low single-digit growth is expected until there is more certainty around various administration policies affecting academic funding and pharmaceutical tariffs [42] Question: Performance of instrumentation in large pharma - Management noted strong growth in instrumentation for large pharma, particularly the LEO system tailored for high throughput applications [44] Question: Commitment to market plus 500 basis points growth - Management acknowledged that in a turbulent environment, achieving that growth may be challenging, but they remain confident in their differentiation from peers [48] Question: Drivers of margin expansion - Margin expansion is expected to be driven by the divestiture of Exosome Diagnostics, which was a headwind to margins in fiscal year 2025 [49] Question: NIH funding sources for academic customers - Management indicated that approximately 50-55% of academic funding comes from federal sources, with NIH accounting for about half of that [51] Question: Outlook for China market - Management highlighted that growth in China was driven by funding releases and anticipation of tariff impacts, with expectations for modest growth moving forward [66] Question: Visibility on biotech funding - Management is monitoring biotech funding closely, noting recent signs of improvement but acknowledging that it remains significantly down year-over-year [93]

Financial Data and Key Metrics Changes - In Q3 2025, total revenue was $144 million, flat year over year on a reported basis and down 2% on an organic basis [17][19] - Adjusted EBITDA margin expanded by approximately 260 basis points year over year to 12.3%, reflecting operational turnaround efforts [9][18] - Free cash flow for the quarter was $15 million, driven primarily by improved working capital [18] Business Line Data and Key Metrics Changes - Sample Management Solutions (SMS) revenue was $78 million, down 4% year over year on a reported basis and down 6% on an organic basis, primarily due to softer bookings and timing delays [20] - Multiomics segment delivered revenue of $66 million, up 4% on a reported basis and up 3% on an organic basis, driven by growth in next-generation sequencing [21][22] - Non-GAAP gross margin for SMS was 53.6%, up 760 basis points year over year, while Multiomics gross margin was 42.6%, down approximately 500 basis points year over year [20][23] Market Data and Key Metrics Changes - China posted 10% organic growth in the Multiomics segment despite macro and geopolitical headwinds [22] - The company anticipates a 1% headwind to full year 2025 revenue due to reductions in NIH funding levels [10][90] Company Strategy and Development Direction - The company is focused on long-term value creation and operational turnaround, with key growth priorities including strengthening commercial excellence and investing in R&D [6][7] - The Azenta Business System (ABS) is being leveraged to enhance operational efficiency and drive growth [8][68] - The company plans to prioritize investments in gross margin productivity, organic growth offerings, and strategic M&A opportunities [12] Management's Comments on Operating Environment and Future Outlook - Management remains committed to full year 2025 guidance of organic revenue growth between 3% to 5% and adjusted EBITDA margin expansion of 300 basis points [9][25] - The company is optimistic about capitalizing on opportunities arising from the current dynamic environment [11] - Management noted that the operational improvements have allowed them to reaffirm guidance despite external challenges [11] Other Important Information - The company ended the quarter with $550 million in cash and no outstanding debt, positioning it well for future investments [12][24] - An Investor Day is planned for later in the calendar year to discuss achievements and outlook [13] Q&A Session Summary Question: Guidance for fiscal 2025 and thoughts on fiscal 2026 - Management indicated confidence in a step-up in Q4 due to momentum in NGS and sufficient backlog, with a commitment to 5% to 8% CAGR for fiscal 2026 [29][34] Question: Weakness in SMS core products - Management clarified that there are no cancellations, but orders are being pushed out due to capital equipment purchase delays [35][36] Question: Gene synthesis headwinds - Management noted softness in gene synthesis from pharma accounts but expects improvements in Q4 [39][40] Question: Q4 revenue expectations - Management highlighted a seasonal step-up from Q3 to Q4 and strong funnel visibility, indicating confidence in achieving revenue targets [44][46] Question: Leadership changes impact - Management discussed new commercial leadership in North America and positive early signs from the regional model [48][50] Question: M&A funnel focus - Management emphasized a disciplined approach to M&A, focusing on core biorepositories and multiomics opportunities [52][54] Question: NIH funding headwinds - Management maintained a consistent view on NIH funding as a 1% headwind but expressed optimism about potential increases in funding [89][90]